Announcements & Circulars-Alphamab Oncology

English 中文简体中文繁体

English 中文简体中文繁体

Investors

Information Disclosure

Listing Documents

Financial Reports

Announcements & Circulars

Company Presentation

Corporate Governance

Stock Information

Corporate Communications

Email Subscription

Announcements & Circulars

The announcement begins in December 2019

VOLUNTARY ANNOUNCEMENT - FIRST PATIENT DOSED IN A PHASE II/III CLINICAL TRIAL OF KN046 IN COMBINATION WITH LENVATINIB FOR THE TREATMENT OF PD-(L)1 REFRACTORY ADVANCED NSCLC 2021-10-28
GRANT OF SHARE OPTIONS 2021-10-25
VOLUNTARY ANNOUNCEMENT - COMPLETION OF PATIENT ENROLLMENT IN A PHASE III CLINICAL TRIAL OF KN046 IN COMBINATION WITH CHEMOTHERAPY IN THE TREATMENT OF ADVANCED UNRESECTABLE OR METASTATIC SQUAMOUS NSCLC 2021-10-15
Monthly Return of Equity Issuer on Movements in Securities for the month ended 30 September 2021 2021-10-08
VOLUNTARY ANNOUNCEMENT - UPDATES ON CLINICAL DATA FROM PHASE II CLINICAL STUDY OF KN046 COMBINED WITH CHEMOTHERAPY IN THE FIRST-LINE TREATMENT OF PDAC FOR PRESENTATION AT 2021 CSCO ANNUAL MEETING 2021-09-17
VOLUNTARY ANNOUNCEMENT - RESEARCH RESULTS ON KN046 AND KN026 FOR PRESENTATION AT ESMO CONGRESS 2021 2021-09-13
Monthly Return of Equity Issuer on Movements in Securities for the month ended 31 August 2021 2021-09-06
INTERIM RESULTS ANNOUNCEMENT FOR THE SIX MONTHS ENDED JUNE 30, 2021 2021-08-27
LIST OF DIRECTORS AND THEIR ROLE AND FUNCTION 2021-08-27
CHANGE OF INDEPENDENT NON-EXECUTIVE DIRECTOR 2021-08-27

15 16 17 18 19 20 21